Why the study?
Primary splenic or hepatic angiosarcomas are ultra-rare, aggressive malignancies with poor prognosis.
This case highlights the aggressive nature of primary splenic/hepatic angiosarcomas and the potential risks of targeted therapies like sunitinib.
Answers are grounded in this paper and cite their sources.
Sunitinib may pose bleeding risk in splenic angiosarcoma; this case leaves open questions on targeted therapy safety.
Primary splenic or hepatic angiosarcomas are ultra-rare and aggressive malignancies associated with poor prognosis. The mainstay treatments are surgical resection and chemotherapy. We report a case of angiosarcoma in a 50-year-old woman who presented with bruising, fatigue, ecchymosis, and hepatosplenomegaly. She was treated with the multi-kinase inhibitor sunitinib for 4 weeks before developing a splenic hemorrhage and succumbing. Recent studies have demonstrated the clinical benefit of immunotherapies in angiosarcomas. Additionally, sequencing techniques have showcased the diverse molecular aberrations involved in angiosarcomas, which offer opportunities for precision-matched targeted therapies such as inhibitors of the VEGF/VEGFR axis and PI3K/Akt/mTor pathway.
No takes yet. Share an insight, caveat, or question.
Deshpande et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: